AB-293-NA

antibody from R&D Systems

Targeting: VEGFA VEGF, VEGF-A, VPF

Western blot (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

AB-293-NA

Provider

R&D Systems

Product name

Human VEGF165 Antibody

Antibody type

Polyclonal

Description

Protein A or G purified. Detects human VEGF165 and human VEGF121 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse VEGF and recombinant rat VEGF is observed.

Reactivity

Human

Host

Goat

Conjugate

Unconjugated

Antigen sequence

AAV38412


Isotype

IgG

Vial size

1 mg

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

Vasculogenic mimicry formation in EBV-associated epithelial malignancies.

Xiang T, Lin YX, Ma W, Zhang HJ, Chen KM, He GP, Zhang X, Xu M, Feng QS, Chen MY, Zeng MS, Zeng YX, Feng L
Nature communications 2018 Nov 27;9(1):5009

---

High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy.

Kivelä AM, Huusko J, Gurzeler E, Laine A, Dijkstra MH, Dragneva G, Andersen CB, Moestrup SK, Ylä-Herttuala S
Scientific reports 2017 Mar 24;7(1):386

---

Extensive podocyte loss triggers a rapid parietal epithelial cell response.

Hakroush S, Cebulla A, Schaldecker T, Behr D, Mundel P, Weins A
Journal of the American Society of Nephrology : JASN 2014 May;25(5):927-38

---

Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.

Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T
Anticancer research 2014 Feb;34(2):671-7

---

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.

Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, Ngan SY, Chander S, Powell GJ, Herschtal A, Te Marvelde L, Desai J, Choong PF, Stacker SA, Achen MG, Ferris N, Fox S, Slavin J, Thomas DM
British journal of cancer 2014 Dec 9;111(12):2254-61

---

Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.

Uniewicz KA, Cross MJ, Fernig DG
The Journal of biological chemistry 2011 Jan 7;286(1):12-23

---

Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus.

Nicoletti JN, Shah SK, McCloskey DP, Goodman JH, Elkady A, Atassi H, Hylton D, Rudge JS, Scharfman HE, Croll SD
Neuroscience 2008 Jan 2;151(1):232-41

---

Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.

Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2001 Sep;30(8):449-57

---

Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.

Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2001 Sep;30(8):449-57

Immunohistochemistry

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

VEGF in Human Breast Cancer Tissue. VEGF was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

VEGF₁₆₅ in Human Breast Cancer Tissue. VEGF₁₆₅ was detected in immersion fixed frozen sections of human breast cancer tissue using 5 µg/mL Human VEGF₁₆₅ Polyclonal Antibody (Catalog # AB-293-NA) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Cell Proliferation Induced by VEGF₁₆₅ and Neutralization by Human VEGF Antibody. Recombinant Human VEGF₁₆₅ (Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF₁₆₅ (10 ng/mL) is neutralized (green line) by increasing concentrations of Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA). The ND₅₀ is typically 0.6-3.0 µg/mL.